Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma
To assess the efficacy of intravitreal aflibercept in patients suffering from post-radiation macular edema following plaque radiotherapy for choroidal melanoma.
This prospective, interventional case series included patients affected by radiation maculopathy (RM) with macular edema secondary to ruthenium-106 plaque brachytherapy for choroidal melanoma. The effect of intravitreal aflibercept on best-corrected visual acuity (BCVA), central foveal thickness (CFT) detected by spectral domain optical coherence tomography (sd-OCT), and Horgan’s grading scale of RM was evaluated throughout the 24-month follow-up. Intraocular pressure (IOP) and possible complications were also recorded.
Nine eyes of 9 patients were included. A mean of 4.4 ± 1.2 injections were given over the 24 months. At the end of follow-up, mean BCVA was significantly improved, from 0.9 ± 0.19 logMAR at baseline to 0.56 ± 0.3 logMAR (P = 0.028), and mean CFT was significantly decreased, from 546 ± 123 μm at baseline to 223 ± 34 μm (P < 0.001). Intravitreal aflibercept lowered baseline maculopathy stage as well. No significant change in IOP values and no complications, such as endophthalmitis, was recorded.
Intravitreal aflibercept is an effective treatment for patients with radiation-induced macular edema, allowing functional and anatomical improvements to be achieved with a relatively low number of injections.
KeywordsIntravitreal aflibercept Plaque brachytherapy Radiation maculopathy
We wish to thank Dott. A. Bridgewood of the Scientific Bureau of the University of Catania for language support.
Compliance with ethical standards
Conflict of interest
Matteo Fallico declares that he has no conflict of interest. Michele Reibaldi declares that he has no conflict of interest. Teresio Avitabile declares that he has no conflict of interest. Antonio Longo declares that he has no conflict of interest. Vincenza Bonfiglio declares that she has no conflict of interest. Argyrios Chronopoulos declares that he has no conflict of interest. Rosario Caltabiano declares that he has no conflict of interest. Corrado Spatola declares that he has no conflict of interest. Andrea Russo declares that he has no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 11.Kim IK, Lane AM, Jain P, Awh C, Gragoudas ES (2016) Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma. Trans Am Ophthalmol Soc 114:T2Google Scholar
- 14.Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Brown DM, CLEAR-IT 2 Investigators (2011) The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 118:1098–1106CrossRefGoogle Scholar
- 15.Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Nguyen QD, CLEAR-IT 2 Investigators (2011) Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age related macular degeneration. Ophthalmology 118:1089–1097CrossRefGoogle Scholar
- 23.Tah V, Orlans HO, Hyer J, Casswell E, Din N, Sri Shanmuganathan V, Ramskold L, Pasu S (2015) Anti-VEGF therapy and the retina: an update. J Ophthalmol 2015:627674Google Scholar
- 32.Pooprasert P, Young-Zvandasara T, Al-Bermani A (2017) Radiation retinopathy treated successfully with aflibercept. BMJ Case Rep 9:2017Google Scholar
- 35.Shah NV, Houston SK, Markoe AM, Feuer W, Murray TG (2012) Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity. Clin Ophthalmol 6:1739–1748Google Scholar
- 37.Park DH, Sun HJ, Lee SJ (2016) A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Int Ophthalmol. https://doi.org/10.1007/s10792-016-0391-4
- 38.Shaikh AH, Toussaint BW, Miller DM, Petersen MR, Foster RE, Riemann CD, Hutchins RK, Sisk RA (2015) Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 46(1):62–66CrossRefGoogle Scholar